NA-Selank Amidate

N-Acetyl Selank Amidate is a terminally modified analog of Selank, generally described as retaining the Selank heptapeptide backbone with N-terminal acetylation and C-terminal amidation. Defensible peer-reviewed, compound-specific biological studies for this exact analog were not found. The conservative route is to cite parent Selank evidence and explicitly state the direct variant gap. Parent Selank has clinical and preclinical literature around anxiety-related endpoints, enkephalin activity, GABAergic neurotransmission genes, and GABA receptor-related mechanisms. Those findings cannot be assumed for the acetylated/amidated analog because terminal changes can alter stability, distribution, receptor interaction, and degradation.

Parent Selank Context

Parent Selank has been studied in anxiety-related clinical research, including a randomized comparison against medazepam in generalized anxiety disorder or neurasthenia ^[1].

Mechanistic Research

Parent Selank altered expression of genes involved in GABAergic neurotransmission in rat frontal cortex and has been studied for GABA receptor-related activity ^[2][3].

Direct Variant Gap

These findings are parent-compound context only; direct evidence for N-Acetyl Selank Amidate was not found.

Analog-Specific Safety Gap

Direct safety data for N-Acetyl Selank Amidate were not found; parent Selank studies cannot establish safety for the terminally modified analog ^[1][2][3].

Modification Caveat

N-terminal acetylation and C-terminal amidation may change degradation, exposure, and biological activity.